There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Sophie Sokolow |
| Institution: | UCLA |
| Department: | School of Nursing |
| Country: | |
| Proposed Analysis: | Currently donepezil is the most prescribed medication for the treatment of cognitive symptoms in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). However the rate of responders are estimated between 15-35% based on the measurment scale and duration of therapy. Donepezil is not currently approved for the treatment of cognitive symptoms in patients with MCI. However, Petersen et al. showed that donepezil reduced the likelyhood of progression from MCI to AD during the first 12-month of treatment, suggesting that donepzeil might be beneficial in subjects with MCI. In this proposal, we would like to examine whether genetic variations contribute to donepezil response on cognitive and executive functions in MCI patients. Previous pharmacogenetic studies in AD suggested a posssible association between higher CYP2D6 actvity and reduced donepezil response in AD patients. Others data indicated a possible associations between ABCB1 polymorphisms and better donepezil response in LOAD. A recent GWAS study identified two loci associated with donepezil response in AD. Pharmacogenomic studies in MCI patients treated with donepezil have not been reported yet. The ADNI1, ADNIGO, ADNI2 data sets are very well suited data sets for our analysis. We propose a GWAS approach to identify pharmacogenetic markers of donepezil response in MCI patients. |
| Additional Investigators | |
| Investigator's Name: | Jerome Rotter |
| Proposed Analysis: | Same as proposed by Dr. Sokolow |
| Investigator's Name: | Liana Apostolova |
| Proposed Analysis: | Same as proposed by Dr. Sokolow |
